Adult stem cell

Insights into North America's Biobanks Market 2020, Featuring Key Player Profiles Including Atlanta Biologicals Inc., BioLifeSolutions Inc. and Thermo Fisher Scientific Inc.

Friday, May 22, 2020 - 10:15pm

Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.

Key Points: 
  • Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.
  • Several advancements have been made in regenerative medicine through stem cell technology over the past decade.
  • Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases.
  • In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved in Biobanks.

Creative Medical Technology Holdings is Granted Patent on Mesenchymal Stem Cells for Female Infertility Pending Quayle Action

Monday, April 20, 2020 - 1:15pm

PHOENIX, April 20, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and Ovarian Aging using Regenerative Cells.

Key Points: 
  • PHOENIX, April 20, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and Ovarian Aging using Regenerative Cells.
  • The patent covers use of mesenchymal stem cells, a class of adult stem cells, for use in treatment of ovarian failure and ovarian aging.
  • A "Quayle Action" is issued when there are minor issues to be resolved in a patent application that is otherwise in condition forallowance.
  • 2017 Jun 15;9:441-447
    View original content to download multimedia: http://www.prnewswire.com/news-releases/creative-medical-technology-hold...
    SOURCE Creative Medical Technology Holdings, Inc.

Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography

Wednesday, April 15, 2020 - 5:00pm

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.

Key Points: 
  • The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.
  • However, high cost related of the stem cell therapy limits the growth of the market.
  • The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.
  • The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority

Friday, April 3, 2020 - 11:59am

NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority (IIA).

Key Points: 
  • NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority (IIA).
  • BrainStorm's CEO Chaim Lebovits, commented, "The Israel Innovation Authority's support of our programs provides further validation for the potential of our treatments to help patients suffering from neurodegenerative disorders.
  • The IIA has supported BrainStorm Cell Therapeutics Ltd. since 2007, providing grants totaling approximately 11.4 million USD in support of the development of NurOwn and other projects.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Global Stem Cells Market (2020 to 2030) - Focus on Clinical Therapies - ResearchAndMarkets.com

Thursday, March 26, 2020 - 2:19pm

The "Global Stem Cells Market: Focus on Clinical Therapies, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Stem Cells Market: Focus on Clinical Therapies, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options.
  • Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms.
  • However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term.

Stem cell-combo therapy could bring long-term relief for gastroparesis

Tuesday, March 17, 2020 - 3:00pm

However, several recent studies have shown the promise of transplantation of various stem cells and progenitor cells as an effective, long-term solution to this condition," he added.

Key Points: 
  • However, several recent studies have shown the promise of transplantation of various stem cells and progenitor cells as an effective, long-term solution to this condition," he added.
  • About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.
  • By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
  • RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells

Thursday, March 5, 2020 - 8:00am

Although non-stem progenitor cells can have therapeutic effects, only tissue stem cells can provide long-term cures.

Key Points: 
  • Although non-stem progenitor cells can have therapeutic effects, only tissue stem cells can provide long-term cures.
  • Although needed in academic stem cell research, stem cell biomanufacturing, and stem cell medicine, adoption of the AlphaSTEM Test has been limited.
  • "There's a lot of misinformation in the stem cell industry about the nature of tissue stem cell preparations and how counting stem cells specifically would solve many of the current problems faced by the industry and patients."
  • The company plans to integrate the new algorithms with existing electronic cell counters to develop the first tissue stem cell counters for tissue stem cell research, tissue stem cell biomanufacturing, and stem cell therapies.

BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update

Monday, February 10, 2020 - 6:00am

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors.
  • NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.
    About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Cancer Stem Cells Market Expected to Generate Revenue of $ 1,722.7 Million, Growing at a CAGR of 10.3% by 2026

Thursday, January 30, 2020 - 1:00pm

Increasing number of patients of cancer, along with the recent technological advancements in cancer stem cells can drive the market by 2026.

Key Points: 
  • Increasing number of patients of cancer, along with the recent technological advancements in cancer stem cells can drive the market by 2026.
  • Driving Factors of Cancer Stem Cells Market:
    Increasing cases of cancer around the globe is noteworthy key factor which rise the cancer stem cells market growth.
  • Asia-Pacific cancer stem cell marketis of $157.26 million in year of 2018.and it is estimated to rise up to 11.2% CAGR.
  • Countries such as India, China, and Japan are the contributors to the growth of regional market
    Top Key Players in Cancer Stem Cell Market:
    Some of the major players in the global cancer stem cells market are:

Cancer Stem Cells Market Expected to Generate Revenue of $ 1,722.7 Million, Growing at a CAGR of 10.3% by 2026

Thursday, January 30, 2020 - 1:00pm

Increasing number of patients of cancer, along with the recent technological advancements in cancer stem cells can drive the market by 2026.

Key Points: 
  • Increasing number of patients of cancer, along with the recent technological advancements in cancer stem cells can drive the market by 2026.
  • Driving Factors of Cancer Stem Cells Market:
    Increasing cases of cancer around the globe is noteworthy key factor which rise the cancer stem cells market growth.
  • Asia-Pacific cancer stem cell marketis of $157.26 million in year of 2018.and it is estimated to rise up to 11.2% CAGR.
  • Countries such as India, China, and Japan are the contributors to the growth of regional market
    Top Key Players in Cancer Stem Cell Market:
    Some of the major players in the global cancer stem cells market are: